NDAORALTABLETPriority Review
Approved
Jan 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRELAY (troglitazone) is an oral tablet small-molecule thiazolidinedione approved in 1997 for type 2 diabetes management. It enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), improving glycemic control in patients with insulin resistance. The drug is now in late-stage lifecycle maturity with loss of exclusivity approaching.
LOE Approaching
With LOE imminent and moderate competitive pressure (30%), the brand team is likely in defensive mode, focusing on retention and managed decline rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRELAY offers limited career growth given its LOE-approaching status and zero linked job count; opportunities are primarily in defensive commercial execution, managed markets, and regulatory compliance. Career advancement is better sought on growth-stage products or newer mechanisms within the sponsor's portfolio.
Brand ManagerSales Representative
Worked on PRELAY at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.